Lenvima (lenvatinib) / Eisai, Merck (MSD) 
Welcome,         Profile    Billing    Logout  
 53 Diseases   490 Trials   490 Trials   8927 News 


12345678910111213...123124»
  • ||||||||||  Lenvima (lenvatinib) / Eisai, Merck (MSD), sorafenib / Generic mfg.
    Review, Journal:  Regulated Cell Death in Lenvatinib Resistance of Hepatocellular Carcinoma: from Molecular Mechanisms to Therapeutic Strategies. (Pubmed Central) -  Mar 14, 2025   
    Particularly, numerous studies have demonstrated that RCD (including apoptosis, autophagy, ferroptosis, cuproptosis and pyroptosis) plays a significant role in the emergence of LR in HCC. This article offers an in-depth review of recent discoveries concerning the mechanisms of LR in relation to RCD and proposes potential strategies to boost the effectiveness of lenvatinib by incorporating RCD modulators.
  • ||||||||||  Lenvima (lenvatinib) / Eisai, Merck (MSD), rofecoxib (TRM-201) / Tremeau Pharma, celecoxib oral / Generic mfg.
    Journal, Adverse events:  Drug-Related Hypertension: A Disproportionality Analysis Leveraging the FDA Adverse Event Reporting System. (Pubmed Central) -  Mar 11, 2025   
    Some drugs, such as rofecoxib, lenvatinib, and celecoxib, were found to appear on both the frequency and signal strength lists. These results contribute to a more comprehensive understanding of the cardiovascular safety profiles of pharmacological agents, suggesting the necessity of blood pressure monitoring following administration.
  • ||||||||||  Lenvima (lenvatinib) / Eisai, Merck (MSD)
    Journal:  The role of Morin in attenuating atherosclerosis via STAT1 pathway inhibition. (Pubmed Central) -  Mar 10, 2025   
    These results contribute to a more comprehensive understanding of the cardiovascular safety profiles of pharmacological agents, suggesting the necessity of blood pressure monitoring following administration. Subsequently, RAW264.7
  • ||||||||||  Retevmo (selpercatinib) / Eli Lilly, Lenvima (lenvatinib) / Eisai, Merck (MSD)
    Review, Journal, IO biomarker:  Transforming thyroid cancer management: the impact of neoadjuvant therapy. (Pubmed Central) -  Mar 10, 2025   
    Similarly, for medullary thyroid cancer, selpercatinib have exhibited interesting response rates, enhancing the feasibility of surgery with reduced morbidity in limited clinical case series of patients with RET mutations...The risk of adverse events, particularly related to the inhibition of the VEGF pathway, necessitates careful patient selection and management. The variability in tumor responses and the potential for serious complications underscore the need for continued research to refine these approaches in this difficult patient population.
  • ||||||||||  Review, Journal:  Recent Developments in the Management of Renal Cell Cancer. (Pubmed Central) -  Mar 6, 2025   
    Dual immunotherapy combinations, such as nivolumab plus ipilimumab, and ICI-vascular endothelial growth factor (VEGF) tyrosine kinase inhibitor (TKI) combinations, including pembrolizumab with axitinib, nivolumab with cabozantinib, and pembrolizumab with lenvatinib, have demonstrated overall survival (OS) benefits in first-line treatment, redefining the standard of care for advanced RCC...Recent results from CONTACT-3 and TiNiVo-2 confirm that ICI rechallenge should be generally discouraged. This review provides a detailed overview of the current evidence supporting immune-based combinations and novel agents such as belzutifan, as well as insights into treatment sequencing strategies for RCC.
  • ||||||||||  Lenvima (lenvatinib) / Eisai, Merck (MSD)
    Journal:  Analysis of immediate 503 thyroid carcinoma deaths: Trend of single institution in 2005-2024. (Pubmed Central) -  Mar 6, 2025   
    Multivariate logistic regression was applied to assess whether the number of patients with anaplastic TC (ATC) at the diagnosis and the number of local-related deaths changed before and after the introduction of Lenvatinib (i.e., 2005-2014 vs. 2015-2024) Results Of the 503 patients, 157 (31%) had ATC, 253 (50%) had papillary TC (PTC), 67 (13%) had follicular TC (FTC), 17 (3%) had poorly differentiated TC, and 9 (2%) had medullary TC...Conclusions ATC, including anaplastic transformation from PTC and FTC, still accounts for approximately 40% of thyroid cancer deaths after the introduction of systematic drug therapy. Respiratory insufficiency is the most common immediate cause of death.
  • ||||||||||  Clinical, Review, Journal, Real-world evidence:  What can real-world data teach us about treating patients with unresectable hepatocellular carcinoma? (Pubmed Central) -  Mar 5, 2025   
    Studies reveal discrepancies in treatmentefficacy and adverse event profiles between RCTs and routine clinical practice,underscoring the need for individualized treatment strategies. RWE highlightsthe influence of liver disease etiology, liver function, and tumor burden ontreatment outcomes, guiding therapy selection.
  • ||||||||||  Keytruda (pembrolizumab) / Merck (MSD), Lenvima (lenvatinib) / Eisai, Merck (MSD)
    Trial primary completion date:  Neoadjuvant Pembrolizumab and Lenvatinib for Renal Cell Carcinoma (clinicaltrials.gov) -  Mar 3, 2025   
    P1,  N=30, Recruiting, 
    Serum IL-6 levels are thought to be involved in the suppression of tumor immunity and are useful in predicting the therapeutic effect of Atezo+Bev treatment. Trial primary completion date: Jan 2025 --> Jun 2026
  • ||||||||||  Lenvima (lenvatinib) / Eisai, Merck (MSD)
    Journal:  Serum Lenvatinib Concentration Monitoring in a Patient With Thyroid Cancer Exhibiting Hand-Foot Syndrome: A Case Report. (Pubmed Central) -  Feb 28, 2025   
    Taken together, our findings suggest the potential application of Prexasertib in combination with Lenvatinib as a promising therapeutic strategy for HCC treatment. This case's findings suggest that serum lenvatinib concentrations are associated with the severity of lenvatinib-induced HFS and that there may be an overlap between drug concentrations, metastatic suppression, and the grade of HFS.
  • ||||||||||  Keytruda (pembrolizumab) / Merck (MSD), Lenvima (lenvatinib) / Eisai, Merck (MSD)
    Enrollment closed, Trial completion date:  PLANE-PC: Pembrolizumab and Lenvatinib in Advanced/Metastatic Neuroendocrine Prostate Cancer (clinicaltrials.gov) -  Feb 28, 2025   
    P2,  N=50, Active, not recruiting, 
    This case's findings suggest that serum lenvatinib concentrations are associated with the severity of lenvatinib-induced HFS and that there may be an overlap between drug concentrations, metastatic suppression, and the grade of HFS. Recruiting --> Active, not recruiting | Trial completion date: Dec 2024 --> Dec 2025
  • ||||||||||  Tyvyt (sintilimab) / Eli Lilly, Lenvima (lenvatinib) / Eisai, Merck (MSD)
    Trial completion date, Trial primary completion date:  Cryoablation Combined with Sintilimab Plus Lenvatinib in Previously Treated Unresectable Liver Metastasis from Solid Tumors (clinicaltrials.gov) -  Feb 27, 2025   
    P2,  N=25, Recruiting, 
    This study demonstrates that envafolimab in combination with lenvatinib exhibits favourable anti-cancer activity and a manageable safety profile for the first-line treatment of patients with unresectable HCC. Trial completion date: Oct 2024 --> Oct 2025 | Trial primary completion date: Oct 2023 --> Oct 2025
  • ||||||||||  Oncorine (recombinant human adenovirus type 5) / Mergen Ltd., Lenvima (lenvatinib) / Eisai, Merck (MSD)
    Trial completion, Phase classification, Enrollment change, Trial completion date, Trial primary completion date:  Oncolytic Virotherapy Plus PD-1 Inhibitor and Lenvatinib for Patients with Advanced Pancreatic Cancer (clinicaltrials.gov) -  Feb 27, 2025   
    P1,  N=56, Completed, 
    Our study demonstrated that the combination therapy (LI) had longer OS and PFS than the lenvatinib monotherapy (L) in lenvatinib-insensitive patients with uHCC. Recruiting --> Completed | Phase classification: P1b --> P1 | N=25 --> 56 | Trial completion date: Mar 2025 --> Apr 2024 | Trial primary completion date: Mar 2025 --> Apr 2024
  • ||||||||||  Lenvima (lenvatinib) / Eisai, Merck (MSD)
    Journal, Real-world evidence:  Real-world outcomes of lenvatinib therapy for advanced neuroendocrine neoplasms. (Pubmed Central) -  Feb 25, 2025   
    The most frequent side effects reported were hypertension (60.6%), fatigue (39.4%), hypothyroidism (21.2%), and diarrhea (18.2%). This real-world cohort demonstrates encouraging evidence of lenvatinib activity in metastatic NENs, even when used at lower doses than previously studied in NENs.
  • ||||||||||  Lenvima (lenvatinib) / Eisai, Merck (MSD)
    Journal:  An Integrated Virtual Screening Platform to Identify Potent Co-Assembled Nanodrugs for Cancer Treatment. (Pubmed Central) -  Feb 24, 2025   
    interactions...RNA sequencing (RNA-seq) analysis revealed that the co-assembled nanodrugs exhibited mechanisms that are distinct from those of single drugs. This study demonstrates the feasibility of utilizing a computational approach combining LBVS and DFT to identify small molecules with co-assembly capabilities, leading to innovative anticancer strategies.